High MET expression level was associated with worse OS after adjustment for other covariates (p = 0.006); HER2 (p = 0.004) and pERK (p = 0.001) expression level differed between tumor regions, with increased HER2 expression level in the LS compared with the TB and IE. The potential downstream markers pS6 and pERK were expressed across tumor regions, providing evidence that resections and biopsies would yield comparative results in clinical trials [113]. This evidence concerns the gene ERBB2 and neoplasm.